AU2002211678A1 - Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype - Google Patents

Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype

Info

Publication number
AU2002211678A1
AU2002211678A1 AU2002211678A AU1167802A AU2002211678A1 AU 2002211678 A1 AU2002211678 A1 AU 2002211678A1 AU 2002211678 A AU2002211678 A AU 2002211678A AU 1167802 A AU1167802 A AU 1167802A AU 2002211678 A1 AU2002211678 A1 AU 2002211678A1
Authority
AU
Australia
Prior art keywords
apolipoprotein
phenotype
lysis
controlling
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211678A
Inventor
Joseph Broderick
Joseph Clark
Daniel Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2002211678A1 publication Critical patent/AU2002211678A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002211678A 2000-10-13 2001-10-12 Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype Abandoned AU2002211678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24017400P 2000-10-13 2000-10-13
US60240174 2000-10-13
PCT/US2001/031909 WO2002030454A1 (en) 2000-10-13 2001-10-12 Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype

Publications (1)

Publication Number Publication Date
AU2002211678A1 true AU2002211678A1 (en) 2002-04-22

Family

ID=22905425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211678A Abandoned AU2002211678A1 (en) 2000-10-13 2001-10-12 Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype

Country Status (3)

Country Link
US (1) US7135305B2 (en)
AU (1) AU2002211678A1 (en)
WO (1) WO2002030454A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002214644A1 (en) * 2000-10-13 2002-04-22 University Of Cincinnati Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
AU2002214644A1 (en) * 2000-10-13 2002-04-22 University Of Cincinnati Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype

Also Published As

Publication number Publication date
US7135305B2 (en) 2006-11-14
US20040102374A1 (en) 2004-05-27
WO2002030454A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2002227234A1 (en) Circulation set for temperature-controlled catheter and method of using the same
AU2002320730A1 (en) Methods and apparatuses for navigating the subarachnoid space
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002227144A1 (en) System and method for controlling patient temperature
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
AU2002211678A1 (en) Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype
AU2002214644A1 (en) Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
AU5642000A (en) Self-induced deletion of dna
AU2841500A (en) Dehiscence gene and methods for regulating dehiscence
AU2002245350A1 (en) Methods for determining the genetic affinity of microorganisms and viruses
AU2002355155A1 (en) Methods for gene disruption and uses thereof
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
AU2001259595A1 (en) Haplotypes of the crybb1 gene
AU2003255504A1 (en) Use of 6 amino-quinoline-5, 8 quinones and nucleic acids associated with senescence for the treatment of tumors
AU2002320835A1 (en) Brain expressed gene and protein associated with bipolar disorder
AU2001284680A1 (en) Haplotypes of the alas2 gene
AU2002246509A1 (en) Method for controlling the manufacture of polycarbonate and the polycarbonate formed thereby
AU2001290603A1 (en) Haplotypes of the or11a1 gene
AU2002360156A1 (en) Isolated peptide of the hepatocyte growth factor and its variants, preparation method and therapeutic use as anti-angiogenic agents
AU2001250530A1 (en) Treatment of conditions of the central nervous system using mycobacteria
AU2001264719A1 (en) Haplotypes of the aanat gene
AU2001290575A1 (en) Haplotypes of the tacr1 gene
AU2002341766A1 (en) Improved methods for treatment with viral vectors
AU2001264939A1 (en) Haplotypes of the pdxk gene